ADAM: A Reversible Male Contraceptive Shows Promise

Men may soon have a new, long-lasting and reversible birth control option. ADAM, an injectable hydrogel, is currently in development and offers a non-hormonal approach to contraception. This innovative method aims to provide a convenient alternative to vasectomy and traditional barrier methods.

How Does ADAM Work?

ADAM is designed to temporarily block the passage of sperm through the vas deferens, the tube that carries sperm from the testicles. The hydrogel, made of polyethylene glycol, is injected into the vas deferens using a minimally invasive procedure. It creates a selective permeability, with a pore size of 10 to 20 nanometers, effectively preventing sperm passage while allowing the diffusion of small molecules [1]. The hydrogel eventually degrades without intervention, restoring fertility.

Key Features and Benefits

• Reversible: Unlike vasectomy, ADAM is not considered a permanent form of contraception.
• Non-Hormonal: ADAM does not involve the use of hormones, potentially avoiding hormone-related side effects.
• Minimally Invasive: The injection procedure is performed using a no-scalpel vasectomy (NSV) approach, requiring only externalization and cannulation of the vas deferens [2].
• Long-Lasting: The contraceptive effect can last for up to two years.
• Minimal Impact on Libido and Testosterone: Early research suggests ADAM does not affect libido or testosterone levels.

Clinical Trial Results and Safety

Initial clinical trials have focused on evaluating the safety of the ADAM system. The hydrogel and its degradation products have been found to be noncytotoxic, nonirritating, nonsensitizing, and nongenotoxic [1]. A two-year in vivo study in a canine model demonstrated minimal tissue reaction following implantation, with no adverse effects reported [1]. The ADAM System consists of a patented hydrogel and a delivery device that automates the injection process [3].

Administration of ADAM

The injection of ADAM is administered through a 24G over-the-needle catheter, utilizing a proprietary automated injector under local or general anesthesia [2].

Looking Ahead

ADAM represents a significant advancement in male contraceptive options. As clinical trials continue, further research will focus on defining the efficacy of ADAM in inducing azoospermia (the absence of sperm in the ejaculate). Contraline, the clinical-stage medical device company developing ADAM, anticipates providing men with a non-permanent contraceptive solution in the near future [3].